CVIR Endovascular最新文献

{"title":"Embolization of ruptured pancreaticoduodenal arcade aneurysms due to median arcuate ligament without celiac artery revascularization: a single-center experience and literature review.","authors":"Rémi Grange, Nicolas Magand, Noémie Lutz, Bertrand Le Roy, Claire Boutet, Sylvain Grange","doi":"10.1186/s42155-025-00534-1","DOIUrl":"10.1186/s42155-025-00534-1","url":null,"abstract":"<p><strong>Background: </strong>The aim of this single-center retrospective study is to evaluate the feasibility, complications, and outcomes of transarterial embolization (TAE) for ruptured pancreaticoduodenal arcades aneurysms (PDAAs) due to median arcuate ligament (MAL), without subsequent revascularization of celiac artery (CA) occlusion/stenosis.</p><p><strong>Methods: </strong>Between January 1^st 2012 and June 1^st 2024, all records from adult patients (≥ 18 years old) referred to our hospital for TAE due to ruptured PDAAs were retrospectively reviewed. All referrals were based on emergency clinical decisions and computed tomography. Procedure data included procedure, type of embolic agent and per-procedural complication. TAE technical success was defined as the cessation of aneurysm opacification immediately after the TAE, based on angiographic findings. Overall technical success was defined as the cessation of aneurysm opacification after TAE or percutaneous salvage approach during the same session. Then, we analyzed all published original articles published between January 2007 and December 2024 on emergency TAE of ruptured PDAAs due to MAL, without subsequent treatment of CA stenosis/occlusion.</p><p><strong>Results: </strong>Nine patients (4 males) were referred for TAE for ruptured PDAAs due to MAL in our center. TAE technical success was achieved in 7/9 patients, and overall technical success was achieved in all patients. There were no major complications. No patients had rebleeding during follow-up. We reviewed four retrospective studies including 29 patients treated for ruptured PDAAs due to MAL without subsequent treatment of CA stenosis/occlusion. No patient received additional treatment for CA stenosis/occlusion. No aneurysm recurrence was diagnosed during the reported follow-up periods ranging from 1 to 65 months.</p><p><strong>Conclusion: </strong>TAE for ruptured PDAAs without CA revascularization is safe and should be considered, although further studies are required to validate its validity and long-term outcomes.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"8 1","pages":"20"},"PeriodicalIF":1.2,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11911276/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143651978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute pulmonary embolism treatment in lung transplant recipients: mechanical thrombectomy and catheter directed thrombolysis.","authors":"Ahmad Arar, Samuel L Rice, Mhd Wisam Alnablsi, Akhilesh Pillai, Jamaal Benjamin, Rehan Quadri, Daniel Lamus, Anil Pillai","doi":"10.1186/s42155-024-00512-z","DOIUrl":"10.1186/s42155-024-00512-z","url":null,"abstract":"<p><strong>Purpose: </strong>Acute pulmonary embolism (PE) presents a significant challenge in lung transplant recipients (LTR), even with prophylactic anticoagulation. Due to the heightened risk of complications in this population, the optimal treatment approach for acute PE remains uncertain. This retrospective case series aims to elucidate the outcomes of percutaneous mechanical thrombectomy with the Inari device (MT) and catheter-directed thrombolysis (CDT) in managing acute PE in lung transplant patients.</p><p><strong>Materials and methods: </strong>This study examines the treatment outcomes of nine consecutive post-lung transplantation patients with acute PE confirmed with Computed Tomography Angiography (CTA). Treatment interventions included either MT or CDT. Follow-up assessments encompassed a minimum of one year and up to 3 years post-treatment, evaluating various parameters including ICU stay, ventricular pressures, pulmonary function, and laboratory tests.</p><p><strong>Results: </strong>Both MT and CDT achieved a 100% technical success rate, leading to the successful restoration of pulmonary blood flow and improvements in hemodynamic parameters, with a one-year survival rate of 100%.</p><p><strong>Conclusion: </strong>Percutaneous treatments, including MT and CDT, demonstrate feasibility and efficacy in managing acute PE among lung transplant patients. These treatments lead to rapid thrombus resolution, post-treatment improvements, and enhanced overall survival.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"8 1","pages":"19"},"PeriodicalIF":1.2,"publicationDate":"2025-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11896909/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143607228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of robotic assistance on the learning curve in endovascular interventions: exploring the role of operator experience with the CorPath GRX system.","authors":"Tatjana Dell, Marilia B Voigt, Alexander Isaak, Alexander Boehner, Claus Pieper, Narine Mesropyan, Patrick Kupczyk, Julian Luetkens, Daniel Kuetting","doi":"10.1186/s42155-025-00529-y","DOIUrl":"10.1186/s42155-025-00529-y","url":null,"abstract":"<p><strong>Purpose: </strong>This study investigates how endovascular interventionalists adapt to using a robotic platform, specifically the CorPath GRX Robotic System, and examines the influence of prior manual catheterization experience.</p><p><strong>Materials and methods: </strong>An in-vitro trial was conducted to assess the adaptation to robot-assisted catheter-guided interventions in comparison to manual catheterization using a neurovascular phantom. Three interventional radiologists (beginner: no manual experience; intermediate: 3 years; expert: 10 years) with varying experience levels performed three corresponding robotic and manual guided superselective catherization tasks with three attempts per position with both approaches. Procedure time and total radiation dose was recorded.</p><p><strong>Results: </strong>For the beginner reduced intervention times were noted using the robot-assisted approach (mean: 123 s) in comparison to manual catheterization (mean: 257 s; p = 0.008), whilst no differences were seen in between procedure durations for the intermediate (mean: 71 s for manual versus 102 s for robotic; p = 0.388) and expert interventionalist (mean: 30 s for manual versus 42 s for robotic; p = 0.479). The beginner also benefited significantly from robot-assisted procedures with lower emitted total radiation doses (mean: 0.007 Gy for manual versus 0.003 Gy for robotic; p = 0.007), while no significant differences are observed for intermediate (mean: 0.002 Gy for manual versus 0.003 Gy for robotic; p = 0.137) and expert practitioners (mean: 0.0008 Gy for manual versus 0.001 Gy for robotic; p = 0.459).</p><p><strong>Conclusion: </strong>Robot-assisted platforms accelerate skill acquisition for beginners while maintaining efficiency for experienced practitioners. However, addressing costs and training requirements is essential for wider adoption and optimized outcomes.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"8 1","pages":"18"},"PeriodicalIF":1.2,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11876475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143544254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The variable use of heparin through intravenous bolus and flush fluid systems during endovascular stroke treatment, a world-wide survey.","authors":"Senta Frol, Faysal Benali, Aymeric Rouchaud, Robrecht R M M Knapen, Wim H van Zwam","doi":"10.1186/s42155-025-00532-3","DOIUrl":"10.1186/s42155-025-00532-3","url":null,"abstract":"<p><strong>Background: </strong>The total amount of heparin administered through flush fluids in stroke patients is not considered in recent trials, possibly influencing main results. We investigated the use of heparin among treating physicians worldwide.</p><p><strong>Methods: </strong>We conducted a survey from November 2022 to January 2023 to identify the variability of heparin administration during stroke endovascular treatment (EVT). We calculated the total heparin dose per hour (IU/h) by adding the intravenous (IV)-bolus dose to the amount administered through flush fluids, calculated by a multiplication of the number of infusion bags, drip rate[mL/h] and heparin concentration[IU/L].</p><p><strong>Results: </strong>A total of 315 participants from different countries worldwide completed the survey and 231/315(73%) respondents administer heparin during EVT. The majority administered heparin only through flush fluids (168/231; 72.7%), followed by both IV-bolus and flush fluids (36/231; 16%), and those who used only an IV-bolus (27/231; 11.7%). From the participants that administer heparin through flush fluids, the median heparin concentration was 2000 IU/L (range:100 IU/L-10000 IU/L). The total heparin dose (administered through flush fluids and IV-bolus) among 23 respondents showed a median of 4650 IU/h (IQR:3432-5900). Among the respondents who administer heparin through IV-bolus only, the median was 5250 IU (IQR:3750-7500).</p><p><strong>Conclusion: </strong>This survey revealed variable heparin doses administered by physicians worldwide during EVT and reflects the lack of international guidelines. Caution is warranted, specifically during complex/long EVT procedures. Furthermore, heparin flush doses should be considered in future trials regarding periprocedural anticoagulants, since imbalances could potentially confound results.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"8 1","pages":"17"},"PeriodicalIF":1.2,"publicationDate":"2025-03-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11872961/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143538092","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of a new Everolimus-coated balloon catheter in an in-vivo porcine peripheral venous model.","authors":"Stavros Spiliopoulos, Lazaros Reppas, Nikolaos Giannikas, Panagiotis Kitrou, Michail Theofanis, Michail Karpetas, Anargyros N Moulas, Ioannis Paraskevopoulos, Amalia I Moula, Kechagias Ioannis, Dimitrios Karnabatidis","doi":"10.1186/s42155-025-00530-5","DOIUrl":"10.1186/s42155-025-00530-5","url":null,"abstract":"<p><strong>Background: </strong>The venous uptake following the application of Everolimus-coated balloons is under reported. We evaluated the feasibility, safety, and Everolimus (EVR) deliverability of a novel non-commercially available Everolimus-Coated Balloon (ECB) catheter in a swine healthy peripheral vein model.</p><p><strong>Methods: </strong>In total 12 ECBs (5.0 μg/mm²) were inflated in 12 venous segments. The primary feasibility endpoint was the successful application of the ECB at the target venous sites. The primary efficacy endpoint was the successful drug uptake by the target venous tissue at 24 h and 7 days, assessed by High Performance Liquid Chromatography combined with tandem mass spectrometry. The primary safety endpoint was freedom from major adverse events.</p><p><strong>Results: </strong>Everolimus was detected in 10 out of 12 (83.33%) tissue samples (all six tissue samples at 24 h post-intervention and in four out of six samples at 7 days). The mean weight of the examined tissue was 0.20604 ± 0.29822 g (range: 0.37475-0.02229 g). The average EVR tissue content detected at 24 h (135.67 ± 204.95 μg/g) was numerically superior, but non-statistically significant to the that detected 7 days post-procedure (96.85 ± 110.89 μg/g). The average quantity of EVR on the balloon after retrieval was 33.9% of the initial drug dose. No adverse events were recorded, and no abnormalities were noted during autopsy.</p><p><strong>Conclusions: </strong>The newly developed ECB successfully delivered Everolimus within the healthy venous wall. No adverse events were noted at a short-term follow-up.</p><p><strong>Relevance statement: </strong>These safety and feasibility results justify further experimental and clinical research to demonstrate the safety efficacy the specific balloon catheter.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"8 1","pages":"16"},"PeriodicalIF":1.2,"publicationDate":"2025-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11867998/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FEMOSEAL CLOSE: multi-centre observational study with FemoSeal™ vascular closure device following peripheral percutaneous endovascular procedures.","authors":"Yann Gouëffic, Koen Deloose, Maxime Dubosq, Thomas Zeller","doi":"10.1186/s42155-025-00522-5","DOIUrl":"10.1186/s42155-025-00522-5","url":null,"abstract":"<p><strong>Background: </strong>The purpose of the FEMOSEAL CLOSE study was to assess the safety and effectiveness of FemoSeal™ vascular closure device in achieving haemostasis following transfemoral peripheral procedures in routine clinical practice.</p><p><strong>Materials and methods: </strong>This prospective, European, multi-centre, single-arm, post-market clinical follow-up study enrolled patients undergoing diagnostic or interventional peripheral endovascular procedures with FemoSeal™ vascular closure device in inpatient or outpatient settings. The primary endpoint was a composite of safety and effectiveness, with effectiveness defined as cessation of arterial bleeding without adjunctive treatment, and safety as freedom from major vascular complications in the first 6 h. Secondary endpoints included: minor access-site complications and major complications 6 h to 30 days post-procedure, and time to haemostasis, ambulation and discharge. Quality of life was assessed at baseline, discharge and 30-day follow-up. Device usability was also surveyed.</p><p><strong>Results: </strong>Between December 2021 and July 2022, 230 patients were enrolled in three European centres. The primary composite endpoint was achieved in 95.1% (215/226) [95% confidence interval: 91.46-97.55] of patients. The effectiveness component was achieved in 96.9% (219/226) [95% confidence interval: 93.70-98.70], and the safety component in 95.2% (220/230) [95% confidence interval: 92.15-97.90] of patients. FemoSeal™ vascular closure device deployment failure occurred in 1.6% (4/230) of cases, with subsequent manual compression achieving haemostasis. The median time to haemostasis was 0.42 min.</p><p><strong>Conclusions: </strong>The study device provides effective haemostasis and low rates of access-site complications up to 30 days post-procedure for patients undergoing peripheral endovascular interventions. It demonstrates good performance with rapid haemostasis.</p><p><strong>Trial registration: </strong>The study is registered at clinicaltrials.gov. (ClinicalTrials identifier: NCT05027698).</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"8 1","pages":"15"},"PeriodicalIF":1.2,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11846783/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143477248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intermittent Echocardiographic Monitoring During Superior Vena Cava Recanalization: A Protocol for Early Recognition and Management of Hemopericardium.","authors":"Kara M Fitzgerald, David S Shin, Eric J Monroe, Matthew Abad Santos, Ethan Hua, Jeffrey Forris Beecham Chick","doi":"10.1186/s42155-025-00524-3","DOIUrl":"10.1186/s42155-025-00524-3","url":null,"abstract":"<p><strong>Purpose: </strong>Endovascular recanalization and stent reconstruction constitute an effective and safe treatment option for symptomatic thoracic central venous obstruction (TCVO). Rare life-threatening adverse events are possible during or immediately following the procedure, with the most feared one being hemopericardium with cardiac tamponade. A technique to improve efficiency in detection and treatment of cardiac tamponade is described.</p><p><strong>Materials and methods: </strong>An institutional protocol was established for intraprocedural transthoracic echocardiographic monitoring during the TCVO recanalization procedures. The lower chest and upper abdomen were prepared within the sterile field. A separate stand was set up with unopened supplies needed for pericardial drain placement. Intermittent echocardiographic monitoring was performed throughout the TCVO procedure using a dedicated curvilinear probe prepared on the field. If indicated, an image guided pericardial drain was placed expeditiously.</p><p><strong>Results: </strong>Four cases of cardiac tamponade were encountered during or immediately post-procedure. All cases demonstrated technically successful and prompt pericardial drain placement with immediate reversal of the tamponade physiology.</p><p><strong>Conclusion: </strong>Echocardiographic monitoring during TCVO reconstruction by interventional radiologists is a useful technique which may aid in early diagnosis and management of cardiac tamponade.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"8 1","pages":"14"},"PeriodicalIF":1.2,"publicationDate":"2025-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11842650/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143460589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment rationale in nutcracker syndrome with concurrent pelvic congestion syndrome.","authors":"Dominik A Steffen, Arash Najafi, Georgios Festas, Christoph A Binkert","doi":"10.1186/s42155-025-00527-0","DOIUrl":"10.1186/s42155-025-00527-0","url":null,"abstract":"<p><p>The optimal management strategy of nutcracker syndrome is debated, especially in the setting of concurrent pelvic congestion syndrome. In this article, we describe our treatment algorithm as illustrated by four different case scenarios. In our experience, renocaval pressure gradients are often inconclusive, but evaluation of the left renal vein waveform as well as a \"test PTA\" with evidence of a waist in the balloon can be helpful in unmasking a relevant stenosis. We consider nutcracker syndrome not to be a contraindication for ovarian vein embolization. Decision for simultaneous or sequential stenting should be based on angiographic findings and clinical course.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"8 1","pages":"13"},"PeriodicalIF":1.2,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11828768/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Percutaneous Closure Device Controlled INCRAFT Stentgraft Implantation Registry (PUCCINI).","authors":"T Engelen, R Hoogervorst, K DeLoose, L C van Dijk, R S van Eps, R B van Tongeren, H T Veger, L Maene, W Stomp, O R Wikkeling, S J C Klink, W van den Eynde, J J Wever, H van Overhagen","doi":"10.1186/s42155-025-00523-4","DOIUrl":"10.1186/s42155-025-00523-4","url":null,"abstract":"<p><strong>Background: </strong>Percutaneous endovascular repair (PEVAR) of infra-renal abdominal aortic aneurysms (AAA) is increasingly being performed due to the development of low profile endografts and the use of percutaneous closure devices. The feasibility and safety of the use of the INCRAFT AAA Stentgraft System and the ProGlide vascular closure system was assessed.</p><p><strong>Methods: </strong>The PUCCINI trial prospectively enrolled patients undergoing elective repair of infrarenal AAA at 3 centres in the Netherlands and 3 centres in Belgium. Patients underwent PEVAR with endograft implantation followed by closure using the ProGlide closure device. Procedural success rates, complications and 30-day follow-up outcomes were collected.</p><p><strong>Results: </strong>A total of 93 patients, 87% male, were enrolled. The mean aneurysmal diameter was 53.9 ± 10.2 mm. Successful ProGlide placement was achieved in 97.2% in the right and 89.8% in the left groin. Successful closure was achieved in 92.4% of right and 90% of left groins. One patient required surgical access and two surgical closure. Average blood loss was 155.6 ± 175.5ml. Blood transfusion was not required. Average length of hospital stay was 2.1 ± 1.3 days. Post-implantation endoleaks were present in 37 (40.2%) patients (type 1: 12, type 2: 25). At 30-days there was no aneurysmal growth and no deaths. Follow-up imaging showed endoleaks in 39 (41.9%) patients. (type 1:8, type 2:29, type 3:2).</p><p><strong>Conclusion: </strong>The results from the PUCCINI trial demonstrate that the use of a low profile endoprosthesis for treatment of infrarenal AAA with percutaneous closure has a high rate of technical success and low rates of periprocedural complication.</p>","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"8 1","pages":"11"},"PeriodicalIF":1.2,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807031/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Axillo-caval extra-anatomic venous bypass creation via direct percutaneous puncture of the superior vena cava.","authors":"Stephan S Leung, Patrick Lee, Anthony N Hage, Robert W Ford","doi":"10.1186/s42155-025-00518-1","DOIUrl":"10.1186/s42155-025-00518-1","url":null,"abstract":"","PeriodicalId":52351,"journal":{"name":"CVIR Endovascular","volume":"8 1","pages":"12"},"PeriodicalIF":1.2,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11807030/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143374913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}